We also showed that contrast with the unfavorable prognosis of pyrimidine metabolic rate–limiting enzymes, purinergic receptors P2RX1, P2RX2, P2RX7, P2RY12, P2RY13, and P2RY14 were favorable prognostic markers in patients with lung cancer (Fig. 5b). This evidence concerns the gene P2RX7 and lung cancer.